Core Insights - INNOVATE Corp. announced that its investment in MediBeacon Inc. has led to the recognition of a peer-reviewed article on transdermal GFR measurement as one of the top five Editor's Choice articles for 2025 by the Journal of the American Society of Nephrology [1][2] Company Overview - INNOVATE Corp. operates in three key areas: Infrastructure, Life Sciences, and Spectrum, employing approximately 3,100 people across its subsidiaries [3] - MediBeacon Inc. specializes in fluorescent tracer agents and transdermal detection technology, holding over 55 granted U.S. patents and more than 250 patents worldwide [4] Product and Technology - The MediBeacon® TGFR™ System includes Lumitrace® (relmapirazin) injection, a reusable sensor, and a monitor, enabling kidney function assessment through transdermal measurement of the clearance rate of the fluorescent agent [7] - Lumitrace® is a non-radioactive, non-iodinated compound designed for GFR tracing, with its fluorescence data collected via a sensor placed on the skin [5] - The TGFR System is approved for human use and is being deployed in key medical centers for applications such as heart failure monitoring and oncology drug dosing [6][2] Clinical Significance - There is a significant clinical need for improved GFR assessment at the point of care, with the transdermal GFR (tGFR) method viewed as a potential game changer in clinical practice [2] - The TGFR System aims to address the limitations of existing GFR assessment methodologies, providing vital measurements of kidney function [2]

Core Insights - INNOVATE Corp. announced that its investment in MediBeacon Inc. has led to the recognition of a peer-reviewed article on transdermal GFR measurement as one of the top five Editor's Choice articles for 2025 by the Journal of the American Society of Nephrology [1][2] Company Overview - INNOVATE Corp. operates in three key areas: Infrastructure, Life Sciences, and Spectrum, employing approximately 3,100 people across its subsidiaries [5] - MediBeacon specializes in fluorescent tracer agents and transdermal detection technology, holding over 55 granted U.S. patents and more than 250 patents worldwide [6] Product Details - The TGFR™ System includes Lumitrace (relmapirazin) injection, a TGFR™ Monitor, and a TGFR™ Reusable Sensor, enabling kidney function assessment through transdermal measurement of Glomerular Filtration Rate (tGFR) [3][9] - Lumitrace is a non-radioactive, non-iodinated compound designed for fluorescence data collection via a sensor placed on the skin, allowing for real-time GFR assessment [7] Clinical Significance - There is a significant clinical need for improved GFR assessment methods, as current methodologies have limitations; the transdermal GFR (tGFR) is viewed as a potential game changer in clinical practice [4] - MediBeacon's TGFR System is being deployed in key medical centers for applications in heart failure monitoring, transplant evaluation, and oncology drug dosing [4][8]

Core Viewpoint - MediBeacon Inc., in which INNOVATE Corp. holds a 44.7% equity interest, has received FDA approval for its next-generation TGFR System, which includes the TGFR Reusable Sensor, enhancing kidney function assessment technology [1][7]. Group 1: Product Details - The TGFR System allows for kidney function assessment at the point of care by measuring the clearance rate of Lumitrace (relmapirazin), a non-radioactive, non-iodinated fluorescent GFR agent [2]. - The TGFR Reusable Sensor is designed for patient comfort, ease of application, and reusability, reducing costs compared to the previously approved single-use TGFR Sensor [3]. - The TGFR System records Lumitrace fluorescence intensity transdermally at a rate of 2.5 readings per second, providing real-time data on kidney function [12]. Group 2: Clinical Validation and Research - The TGFR System was featured in a lead peer-reviewed article in the Journal of the American Society of Nephrology, highlighting its application across various levels of kidney function and skin colors [4]. - MediBeacon has a strong research background with over 700 peer-reviewed publications and conference abstracts utilizing the transdermal GFR methodology [5]. Group 3: Market Strategy and Future Plans - MediBeacon plans to offer early access to the TGFR System at leading academic medical centers in the U.S. and China, with initial sales expected to begin in the first quarter of 2026 [5][7]. - The company aims to integrate transdermal GFR technology into ongoing heart failure studies, emphasizing its potential to improve patient monitoring and accuracy in kidney function assessment [6]. Group 4: Company Overview - INNOVATE Corp. is focused on key areas of the new economy, including Infrastructure, Life Sciences, and Spectrum, employing approximately 3,100 people across its subsidiaries [8]. - MediBeacon specializes in fluorescent tracer agents and transdermal detection technology, holding over 60 granted U.S. patents and more than 245 patents worldwide [9].